Last updated: February 20, 2026
Which companies manufacture Iothalamate Meglumine?
Multiple pharmaceutical companies produce Iothalamate Meglumine, a radiocontrast agent used in imaging procedures. The primary suppliers are based in the United States, Europe, and Asia.
Key Manufacturers
| Company |
Location |
Market Presence |
Production Capacity |
Notes |
| Bayer Healthcare (now part of Siemens Healthineers) |
Germany |
Global |
High |
Historically dominant in contrast media products |
| GE Healthcare |
United States |
Global |
Significant |
Supplies imaging agents including Iothalamate Meglumine |
| Guerbet S.A. |
France |
Europe, Global |
Moderate |
Manufactures contrast media for diagnostic imaging |
| Bracco Imaging S.p.A. |
Italy |
Europe, Global |
Moderate |
Produces contrast agents, including Iothalamate-based compounds |
| WuXi AppTec |
China |
Asia, Global |
Growing |
Offers contract manufacturing for contrast agents |
| Chengdu West Abio-Pharm Co., Ltd. |
China |
Asia |
Niche |
Produces radiocontrast media including Iothalamate derivatives |
Additional Suppliers
Emerging markets and contract manufacturing organizations (CMOs) supply Iothalamate Meglumine through licensing agreements. Market entry remains restricted by regulatory approvals and production capacity limitations.
Manufacturing and Regulatory Status
| Country |
Regulatory Approval |
Major Brands |
Notes |
| United States |
FDA-approved |
Bayer, GE |
Market control held by a few major players |
| European Union |
EMA approval |
Guerbet, Bracco |
Stringent manufacturing standards for safety and efficacy |
| China |
CFDA approval |
WuXi AppTec, Chengdu West Abio-Pharm |
Rapidly expanding manufacturing capacity |
Industry Trends
- Generic Production Increase: Several manufacturers are developing generic versions, primarily targeting emerging markets.
- Regulatory Hurdles: Approvals depend heavily on regional compliance with safety standards set by the FDA, EMA, and other agencies.
- Supply Chain Consolidation: Major suppliers like Bayer, GE, and Guerbet focus on expanding production to meet global demand, especially for diagnostic imaging amid growing healthcare needs.
Market Dynamics and Competition
The competitive landscape centers on manufacturing capacity, regulatory approval, and distribution networks. Limited number of manufacturers globally maintains high barriers to entry. Disruptive innovations in contrast media formulations are under development but have yet to penetrate the market significantly.
Summary
- Major suppliers: Bayer (Siemens Healthineers), GE Healthcare, Guerbet, Bracco.
- Regional manufacturing hubs: United States, Germany, France, Italy, China.
- Supplies are regulated by regional authorities, with approvals necessary for market presence.
- Supply chain stability depends on regulatory compliance and capacity expansion.
Key Takeaways
- Iothalamate Meglumine has a concentrated supply chain dominated by few large players.
- Regional regulatory standards influence manufacturing locations and capacity.
- Growing demand in imaging procedures sustains market competition.
- Contract manufacturing organizations expand supply options, especially in Asia.
- Market entry barriers include regulatory approval and manufacturing scale.
FAQs
1. Are there generic alternatives to Iothalamate Meglumine?
Yes, several manufacturers produce generic contrast agents based on Iothalamate compounds, primarily targeting developing markets.
2. Which regions have the most manufacturing capacity for Iothalamate Meglumine?
The United States and Europe hold the majority of manufacturing capacity, with China rapidly increasing production.
3. What regulatory agencies approve Iothalamate Meglumine?
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approve formulations, with regional approvals necessary elsewhere.
4. How does supply chain disruption affect the availability of Iothalamate Meglumine?
Disruptions in manufacturing or regulatory delays can decrease availability, impacting imaging service providers.
5. Are new formulations or alternatives under development?
Research continues into low-osmolar and iso-osmolar contrast agents, but significant shifts in supply depend on regulatory approval and clinical adoption.
References
- Food and Drug Administration. (2023). Approved Drug Products with Therapeutic Equivalence Evaluations.
- European Medicines Agency. (2023). Medicine Approval Documents.
- Markets and Markets. (2022). Contrast Media Market Research Report.
- Euromonitor International. (2022). Global Imaging Agents Industry Overview.
- Pharma Intelligence. (2023). Contract Manufacturing and Supply Chain Trends in Contrast Media.
